Eine Plattform für die Wissenschaft: Bauingenieurwesen, Architektur und Urbanistik
Parkinson Disease ‐Targeted Nanocapsules for Synergistic Treatment: Combining Dopamine Replacement and Neuroinflammation Mitigation
AbstractParkinson's disease (PD) is characterized by dopamine (DA) neuron loss and neuroinflammation. This study develops carrier‐free nanocapsules (NCs) for targeted delivery of DA and catalase (CAT) to the PD brain, addressing both DA depletion and neuroinflammation simultaneously. The NCs are engineered by DA and 4‐formylphenylboronic acid co‐loading with cRGD‐modified CAT (CAT‐cRGD) and surface‐modifying with Angiopep‐2 (Ang). Ang targets the blood‐brain barrier (BBB), enhancing brain delivery, while cRGD targets upregulated integrin receptors in the PD‐affected BBB. The NCs showed a 1.4‐fold increase in parkinsonian brain targeting efficiency compared to normal mice. In PD mice models, NCs demonstrated a stable increase in learning and memory, enhanced locomotor activity, and improved motor coordination. DA supplementation significantly enhanced dopaminergic signaling, increasing DA levels 1.8‐ and 3.5‐fold in the striatum and substantia nigra, respectively. Additionally, delivered CAT effectively reduced neuroinflammation by mitigating endoplasmic reticulum stress, slowing disease progression, and protecting DA from oxidation. This innovative approach using PD‐targeted NCs represents a synergistic strategy for PD treatment, combining symptomatic relief with disease progression intervention.
Parkinson Disease ‐Targeted Nanocapsules for Synergistic Treatment: Combining Dopamine Replacement and Neuroinflammation Mitigation
AbstractParkinson's disease (PD) is characterized by dopamine (DA) neuron loss and neuroinflammation. This study develops carrier‐free nanocapsules (NCs) for targeted delivery of DA and catalase (CAT) to the PD brain, addressing both DA depletion and neuroinflammation simultaneously. The NCs are engineered by DA and 4‐formylphenylboronic acid co‐loading with cRGD‐modified CAT (CAT‐cRGD) and surface‐modifying with Angiopep‐2 (Ang). Ang targets the blood‐brain barrier (BBB), enhancing brain delivery, while cRGD targets upregulated integrin receptors in the PD‐affected BBB. The NCs showed a 1.4‐fold increase in parkinsonian brain targeting efficiency compared to normal mice. In PD mice models, NCs demonstrated a stable increase in learning and memory, enhanced locomotor activity, and improved motor coordination. DA supplementation significantly enhanced dopaminergic signaling, increasing DA levels 1.8‐ and 3.5‐fold in the striatum and substantia nigra, respectively. Additionally, delivered CAT effectively reduced neuroinflammation by mitigating endoplasmic reticulum stress, slowing disease progression, and protecting DA from oxidation. This innovative approach using PD‐targeted NCs represents a synergistic strategy for PD treatment, combining symptomatic relief with disease progression intervention.
Parkinson Disease ‐Targeted Nanocapsules for Synergistic Treatment: Combining Dopamine Replacement and Neuroinflammation Mitigation
Advanced Science
Liu, Ziyao (Autor:in) / Xiang, Shijun (Autor:in) / Chen, Bei (Autor:in) / Li, Jian (Autor:in) / Zhu, Dingcheng (Autor:in) / Xu, Hongjuan (Autor:in) / Hu, Shuo (Autor:in)
Advanced Science ; 11
01.12.2024
Aufsatz (Zeitschrift)
Elektronische Ressource
Englisch
Targeted delivery and thermo/pH-controlled release of doxorubicin by novel nanocapsules
British Library Online Contents | 2018
|British Library Online Contents | 2009
|Parkinson-s disease: considerations for dental hygienists
British Library Online Contents | 2013
|Plaque‐Targeted Rapamycin Spherical Nucleic Acids for Synergistic Atherosclerosis Treatment
Wiley | 2022
|Trans Tech Publications | 2010